Clinical trials
Age-Related Macular Degeneration clinical trials
Below are recruiting age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07053358RecruitingEarly Phase 1
Gene therapy for wet AMD
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
ShanghaiAges 50 years+ - NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT06718816Recruiting
Long-term follow-up of AL-001 eye injection for wet AMD
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
Beijing, Beijing MunicipalityAges 50 years+ - NCT05986864RecruitingPhase 1/Phase 2
Gene therapy injection for wet AMD
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
St. Petersburg, FloridaAges 50 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT06141460RecruitingPhase 1/Phase 2
Gene therapy trial for wet age-related macular degeneration
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Tianjin, Tianjin MunicipalityAges 50 years+ - NCT05706896Recruiting
Cord blood plasma injections for dry macular degeneration
This trial tests whether injections made from umbilical cord blood “platelet-rich plasma” can improve vision in people with dry age-related macular degeneration (AMD) in both eyes. It targets older adults with specific vision levels and no major other eye or medical problems that could affect the results.
RomeAges 65 years+ - NCT06487039RecruitingPhase 2
EB-203 for wet age-related macular degeneration
This trial tests a new medicine called EB-203 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. It aims to see if the treatment is safe and can help improve or stabilize vision.
BusanAges 50 years+ - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT06536062Recruiting
Cord blood and platelet plasma for dry macular degeneration
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
Rome, RomeAges 65 years+ - NCT06492863RecruitingPhase 1/Phase 2
Gene therapy (FT-003) for wet AMD
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
Tianjin, Tianjin,ChinaAges 50–80 - NCT07275840RecruitingPhase 2
Testing IBI302 for wet age-related macular degeneration
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Gilbert, ArizonaAges 60 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Phoenix, ArizonaAges 50 years+ - NCT05210803Enrolling by invitationPhase 2
Long-term safety follow-up for wet AMD treatment
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
Phoenix, ArizonaAges Any age - NCT06952452RecruitingPhase 3
Testing genes to improve AMD treatment
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
San Cristóbal de La Laguna, Santa Cruz De TenerifeAges 50 years+ - NCT07185841RecruitingPhase 1/Phase 2
Oral tablets for wet macular degeneration
This trial tests an experimental oral tablet for people with wet age-related macular degeneration. It may offer a new way to treat the condition without frequent eye injections.
BeijingAges 50–85 - NCT07547228RecruitingPhase 1/Phase 2
PRL3-zumab for advanced age-related macular degeneration
This study tests a new injectable medicine called PRL3-zumab for patients with advanced wet macular degeneration (nAMD) whose condition hasn't improved enough with standard treatments. The goal is to see if this new approach can help preserve or improve vision in people who have already tried at least two other eye injections.
SingaporeAges 18 years+ - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT06351605Recruiting
Light therapy study for dry age-related macular degeneration
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
OsloAges Any age - NCT06165068RecruitingPhase 3
Antiplatelet and antioxidant drugs for dry AMD with drusen
This study tests whether antiplatelet drugs (like aspirin) and antioxidants can slow the growth of drusen (yellow deposits) in dry age-related macular degeneration (AMD). It may help prevent the disease from worsening.
Bangkok, DusitAges 50–85 - NCT07005323Recruiting
New treatment for resistant wet AMD
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
Ube, YmaguchiAges 50–85 - NCT07423429Recruiting
Switching to Aflibercept 8 mg for wet AMD
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Nantes, NantesAges 18 years+
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for age-related macular degeneration?
- Yes. Clin2 currently lists 138 recruiting age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.